The fact that, in RMS and NB, ITGA9 can discriminate a subgroup of patients with worse prognosis should be considered for subsequent studies, as this new set of patients with worst prognosis would be candidates for putative ITGA9-based anti-metastatic therapy or, at least, for an intensification of treatment owing to their putative propensity to metastasize. The gene discussed is ITGA9; the disease is neuroblastoma.